SCI Abstract

search
+
Where Are All the Women in Industry Advisory Boards?
Where Are All the Women in Industry Advisory Boards?
In this article academic and industry professionals partner to explore the causes and consequences of gender & other d...
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based...
Guilt and Gratitude
Guilt and Gratitude
Guilt and Gratitude: Guilt surrounding toxic consequences of chemotherapy and gratitude to patients for acknowledging the ...
Dissecting the Need for Adjuvant Therapy in Patients With Early-Stage Melanoma With Micrometastases
Dissecting the Need for Adjuvant Therapy in Patients With Early-Stage Melanoma With Micrometastases
© 2022 by American Society of Clinical OncologyAUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTDissecting the Need ...
Line by Line: Distinct Patterns of Anti-EGFR Antibody Resistance by Line of Therapy
Line by Line: Distinct Patterns of Anti-EGFR Antibody Resistance by Line of Therapy
Line by Line: Distinct Patterns of Anti-EGFR Antibody Resistance by Line of TherapyThe following represents disclosure inf...
Symptom Clusters in Childhood Cancer Survivors
Symptom Clusters in Childhood Cancer Survivors
© 2022 by American Society of Clinical OncologyTHE TAKEAWAYIn the article accompanying this editorial, Shin et al4 describ...
Resistance Mechanisms to Anti–Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy
Resistance Mechanisms to Anti–Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy
PURPOSEAcquired resistance to anti–epidermal growth factor receptor (EGFR) inhibitor (EGFRi) therapy in colorectal cancer ...
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based...
Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis
Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis
PURPOSEBinary cardiac response assessment using cardiac biomarkers is prognostic in light chain amyloidosis. Previous stud...
Redefining Gleason 6 Prostate Cancer Nomenclature: The Surgeon's Perspective
Redefining Gleason 6 Prostate Cancer Nomenclature: The Surgeon's Perspective
AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTRedefining Gleason 6 Prostate Cancer Nomenclature: The Surgeon's Pe...
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
PURPOSECheckMate 651 (ClinicalTrials.gov identifier: NCT02741570) evaluated first-line nivolumab plus ipilimumab versus EX...
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network
PURPOSEHydroxyurea (HY) is a reference treatment of advanced myeloproliferative neoplasms. We conducted a randomized phase...
Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia
Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia
PURPOSEGermline missense variants of unknown significance in cancer-related genes are increasingly being identified with t...
Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial
Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial
PURPOSEWe determined the safety and efficacy of coadministration of CD19- and CD22-chimeric antigen receptor (CAR) T cells...
State Variation in Squamous Cell Carcinoma of the Anus Incidence and Mortality, and Association With HIV/AIDS and Smoking in the United States
State Variation in Squamous Cell Carcinoma of the Anus Incidence and Mortality, and Association With HIV/AIDS and Smoking in the United States
PURPOSESquamous cell carcinoma of the anus (SCCA) incidence and mortality rates are rising in the United States. Understan...
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial
PURPOSEWe evaluated the efficacy and safety of pembrolizumab in patients from Asia with previously treated advanced hepato...
High Diagnostic Accuracy of Epigenetic Imprinting Biomarkers in Thyroid Nodules
High Diagnostic Accuracy of Epigenetic Imprinting Biomarkers in Thyroid Nodules
PURPOSETo explore the novel diagnostic value of epigenetic imprinting biomarkers in thyroid nodules.PATIENTS AND METHODSA ...
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials
PURPOSEOxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer (CC) for 6 months remains a standar...
The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?
The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?
The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?The following represents disclosure information...
format_indent_increase